

## **Bactericidal Activity of Normal Bovine Serum (NBS) Directed against Some *Enterobacteriaceae* with Sialic Acid-containing Lipopolysaccharides (LPS) as a Component of Cell Wall**

GABRIELA BUGLA-PŁOSKOŃSKA\* and WŁODZIMIERZ DOROSZKIEWICZ

Institute of Genetics and Microbiology University of Wrocław  
Przybyszewskiego 63/77, 51-148 Wrocław, Poland

Received 28 April 2006, accepted 15 June 2006

### **Abstract**

The sensitivity of bacteria to the bactericidal activity of serum depends on the structure and organization of the bacterial outer membrane. Sialic acid has been found in the O-specific region of bacterial lipopolysaccharide (LPS) and it plays an essential role in protecting Gram-negative bacteria against the bactericidal activity of human and animal serum. The susceptibility of Gram-negative bacilli with sialic acid-containing LPS to the bactericidal action of normal bovine serum (NBS) was determined. The examined strains (*Escherichia coli* O104 (PCM 270), *E. coli* O24 (PCM 195), *E. coli* O56 (PCM 2372), *Citrobacter braakii* O37 (PCM 2346) and *Salmonella enterica* ssp. *enterica* serovar Toucra O48 (PCM 2359) showed variable sensitivity to the bactericidal effect of the serum. The role of the mechanisms of complement activation in the killing process was also determined.

**Key words:** Gram-negative bacteria, lipopolysaccharide, normal bovine serum (NBS), sialic acid

### **Introduction**

The complement system plays an important role in protection higher organisms against bacterial infection. The complement system can be activated in three ways, known as: the classical, lectin, and alternative pathways. The classical pathway plays the most important role in the bactericidal action of serum. The alternative and the lectin pathways are considered to be less important. The latter two pathways can be activated with or without the participation of antibodies. Activation of the classical complement pathway is dependent on the recognition of antigen by IgG or IgM antibodies, whereas activation of the alternative and lectin pathways is not necessarily dependent on the presence of antibody and is therefore a first line of defense for the host organism (Mokracka-Latajka *et al.*, 1996; Matsushita *et al.*, 1998; Rautemaa and Meri, 1999).

The sensitivity of Gram-negative rods to the bactericidal action of serum depends on their cell wall structure. The phenomenon of serum resistance of bacteria has a multifactorial basis, and the structure of the outer membrane has an essential role in protecting Gram-negative bacteria against the action of serum. The O-specific side chains of lipopolysaccharides (LPS), capsules and outer membrane proteins (OMP) play a decisive role in this phenomenon (Lachowicz *et al.*, 1999; Mielnik *et al.*, 2001; Cisowska and Jankowski, 2004; Bugla *et al.*, 2004).

Sialic acids (*N*-acetylneuraminic acid) are important constituents of glycoconjugates in animal tissues. In eukaryotic cells, sialic acids stabilize glycoconjugates, mediate cell-cell regulation, and regulate transmembrane receptor function (Vimiri *et al.*, 2004). Sialic acid is not a common component within the bacterial cell, but may occur as a component of the capsule, *e.g.* K1 and K92 antigens in *E. coli*, type III capsular polysaccharides of streptococci of group B, capsules of meningococci of serogroup B, (Egan *et al.*, 1977; Marques *et al.*, 1992; Ram *et al.*, 1999) or as a component of LPS. The sialic acid has been found in LPS of *E. coli* (serotypes O24; O56; O104) (Jann and Jann, 1977; Orskov *et al.*, 1977; Gamian *et al.*, 1992;

\* Corresponding author: Gabriela Bugla-Płoskońska, Institute of Genetics and Microbiology University of Wrocław, Przybyszewskiego 63/77, 51-148 Wrocław, Poland, tel.: + 48 71 3756 306, fax + 48 71 325 21 51, e-mail: gbploskonska@poczta.onet.pl, gabi@microb.uni.wroc.pl

Gamian *et al.*, 1994), *Salmonella* Toucra O48 (Kędzierska, 1978; Gamian *et al.*, 2000), *Hafnia alvei* (Romanowska *et al.*, 1988; Gamian *et al.*, 1991) and *Citrobacter braakii* O37 (Gamian *et al.*, 1992a). Serotype O48 *Salmonella* belongs to clinically important bacteria causing intestinal disfunctions and diarrhoea (Nastasi *et al.*, 1988; Gamian *et al.*, 2000). The presence of sialic acid in the O-chain of LPS was finally proven in 1991 (Gamian *et al.*, 1991). The occurrence of sialic acid in the lipopolysaccharides of the Gram-negative *Enterobacteriaceae* is presented in Table I.

Table I  
The occurrence of sialic acid in the lipopolysaccharides in some representatives of *Enterobacteriaceae*

Strain	Structure	References
<i>Escherichia coli</i> O104	$\rightarrow 3)\beta\text{DGalp}(1\rightarrow 3)\beta\text{DGalpNAc}(1\rightarrow 4)\alpha\text{DGalp}(1\rightarrow 4)\alpha\text{DNeup}5,7,9(\text{Ac})_3(2\rightarrow$	(Gamian <i>et al.</i> , 1992)
<i>Escherichia coli</i> O24	$\alpha\text{DGlcP}$ $\downarrow 1, 2$ $\rightarrow 3)\beta\text{DGlcP}(1\rightarrow 3)\beta\text{DGalpNAc}(1\rightarrow 7)\alpha\text{DNeup}5\text{Ac}(2\rightarrow$	(Gamian <i>et al.</i> , 1994)
<i>Escherichia coli</i> O56	$\alpha\text{DGalP}$ $\downarrow 1, 2$ $\rightarrow 3)\beta\text{DGlcP}(1\rightarrow 3)\beta\text{DGlcPNAc}(1\rightarrow 7)\alpha\text{DNeup}5\text{Ac}(2\rightarrow$	(Gamian <i>et al.</i> , 1994)
<i>Salmonella</i> Toucra O48	$\rightarrow 3)\alpha\text{LFucpNAc}(1\rightarrow 3)\beta\text{DGlcPNAc}(1\rightarrow 4)\alpha\text{DNeup}5\text{Ac}(2\rightarrow$	(Gamian <i>et al.</i> , 2000)
<i>Citrobacter braakii</i> O37	$\rightarrow 3)\text{LFucpNAc}(1\rightarrow 3)\text{GlcPNAc}(1\rightarrow 7)\alpha\text{Neup}5\text{Ac}(2\rightarrow$	(Gamian <i>et al.</i> , 1992a)

In the pathogenesis of Gram-negative bacilli sialic acid plays an essential role in protecting them against the bactericidal activity of serum by inhibition of the alternative pathway of complement activation. The presence of sialic acid on the bacterial surface and its direct interaction with factor H of complement can provide resistance against complement attack (Rautemaa and Meri, 1999). Sialic acid may also contribute to the pathogenicity of bacteria by taking part in epitopes that resemble host tissue components (molecular mimicry). Interesting phenomenon of the molecular mimicry was observed in the case of the LPS of *C. braakii* O37 which shared epitopes with equine and human erythrocytes. This serological mimicry may contribute to the pathogenicity of these bacteria (Gamian, 1996). Gamian *et al.* (1992b) reported that the other erythrocytes tested namely sheep, goat, pig, cat and bovine were not agglutinated by anti-O37 *Citrobacter* serum.

In our laboratory we analyzed the mechanisms of the activation of complement in NBS by *Escherichia*, *Citrobacter* and *Salmonella* strains containing LPS with sialic acid. Our previous results (Mielnik *et al.*, 2001) indicated that the strains of Gram-negative rods possessing sialic acid in the O-specific antigen demonstrate different degrees of sensitivity to the bactericidal activity of normal cord serum which indicates that the presence of *N*-acetylneuraminic acid in LPS does not play a decisive role in determining of bacterial resistance to the bactericidal complement activity of normal cord serum.

The scope of the present investigation was to determine the effect of the presence of *N*-acetylneuraminic acid in the LPS structure on the sensitivity of Gram-negative bacilli to the bactericidal activity of NBS.

## Experimental

### Materials and Methods

**Bacterial strains.** The study was carried out on Gram-negative strains which contain sialic acid in the O-specific side chain of LPS. The tested strains were: *Escherichia coli* O104 (PCM 270), *E. coli* O24 (PCM 195), *E. coli* O56 (PCM 2372), *Citrobacter braakii* O37 (PCM 2346) and *Salmonella enterica* ssp. *enterica* serovar Toucra O48 (PCM 2359). The strains were kindly provided by Polish Collection of Microorganisms (PCM) in Wrocław.

**Serum.** Normal bovine serum (NBS) was obtained from five healthy animals not treated with any antimicrobial drug. The serum samples were collected, pooled and kept frozen ( $-70^{\circ}\text{C}$ ) for a period no longer than three months. The suitable volume of serum was thawed immediately before use. Each portion was used only once.

**Medium.** YP broth (bactopeptone, yeast extract and NaCl, pH 7.0) was used as the liquid medium.

**Bactericidal activity of NBS.** The bactericidal activity of NBS was determined as described previously (Doroszkiewicz, 1997). Briefly, the strains were grown overnight, and then bacterial cells in an early exponential growth phase were transferred to fresh YP and incubated at  $37^{\circ}\text{C}$  for 1 hour. After incubation, the bacterial cells were centrifuged (4000 rpm for 20 min) and suspended in saline. Then the bacteria were mixed with 12.5, 25, 50 or 75% NBS (the serum was diluted with 0.1 M NaCl). Bacteria with serum were incubated in a water bath at  $37^{\circ}\text{C}$ . After 0, 60 and 180 min, samples were collected, diluted, and cultured on nutrient agar plates for 18 h at  $37^{\circ}\text{C}$ . The number of colony forming units (CFU) at time 0 was taken as 100%. Strains, which had a survival above 100% after 180 min of incubation in NBS, were regarded as resistant.

**Thermal inactivation of serum.** The control was NBS decomplemented by heating the sample at 56°C for 30 min (NBS 56°C).

**Treatment of sera.** The alternative pathway of complement activation was blocked by incubation of NBS for 20 min at 50°C (NBS 50°C) (Edinger *et al.*, 1977). The classical and lectin pathways of complement activation were inhibited using ethylene glycol-bis ( $\beta$ -aminoethyl ether) *N,N,N',N'*-tetraacetic acid (EGTA) (NBS MgEGTA). This effect of preparation was obtained by removing of cations  $Ca^{2+}$  from serum by EGTA supplemented with  $MgCl_2$ . The final concentration of EGTA and  $MgCl_2$  in the serum was 10 mmol/l. The EGTA solution was prepared according to Fine *et al.* (1972).

## Results

Four serum concentrations (12.5%, 25%, 50% and 75%) were used. The tested strains demonstrated varied resistance to the bactericidal activity of NBS. Two strains: *E. coli* O24, and *E. coli* O104, were resistant to the bactericidal effect of complement protein. *E. coli* O56, *C. braakii* O37, and *S. Toucra* O48 demonstrated higher sensitivity to the bactericidal activity of complement than the *E. coli* O24, and *E. coli* O104 strains, and NBS bactericidal activity was more effective against these strains. To determine the effect of incubation time on killing of the bacterial cell, we determined the survival of bacteria after one and three hours. It was shown that for *E. coli* O56, *Citrobacter braakii* O37, and *S. Toucra* O48 strains, one hour of incubation was sufficient to achieve a high bactericidal effect of the serum. The results concerning the sensitivity of the Gram-negative bacilli with sialic acid-containing LPS to NBS are given in Tables II–VI. As shown in these tables the bacteria proliferated very intensively in the inactivated NBS (NBS 56°C).

In next step we determined the role of the particular mechanisms of complement activation in the killing of Gram-negative bacilli with sialic acid-containing LPS. We examined the biological activity of serum in which the alternative pathway of complement activation was thermally inhibited (NBS 50°C) and serum in which

Table II

Bactericidal activity of NBS against *Escherichia coli* O56

Time of incubation (min)	Serum concentration (%)				
	12.5	25	50	75	75 <sup>c</sup> <sub>(NBS 56°C)</sub>
	CFU <sup>a</sup>				
0	$69 \times 10^5$	$29 \times 10^5$	$21 \times 10^5$	NT <sup>b</sup>	$81 \times 10^5$
60	$41 \times 10^4$	$60 \times 10^3$	$17 \times 10^2$	NT	$50 \times 10^6$
180	$56 \times 10^4$	$36 \times 10^2$	$11 \times 10^1$	NT	$22 \times 10^7$

<sup>a</sup> CFU, colony forming units (relevant for Tables II–VI)

<sup>b</sup> NT, not tested (relevant for Tables II–VI)

<sup>c</sup> NBS, decomplemented by heating at 56°C for 30 min (relevant for Tables II–VI)

Table III

Bactericidal activity of NBS against *Escherichia coli* O104

Time of incubation (min)	Serum concentration (%)				
	12.5	25	50	75	75 <sub>(NBS 56°C)</sub>
	CFU				
0	NT	$35 \times 10^4$	$26 \times 10^5$	$45 \times 10^5$	$58 \times 10^5$
60	NT	$11 \times 10^5$	$68 \times 10^5$	$39 \times 10^5$	$31 \times 10^6$
180	NT	$51 \times 10^5$	$13 \times 10^7$	$15 \times 10^6$	$37 \times 10^7$

Table IV

Bactericidal activity of NBS against *Escherichia coli* O24

Time of incubation (min)	Serum concentration (%)				
	12.5	25	50	75	75 <sub>(NBS 56°C)</sub>
	CFU				
0	$59 \times 10^5$	$43 \times 10^5$	$21 \times 10^5$	$22 \times 10^5$	$70 \times 10^5$
60	$35 \times 10^6$	$13 \times 10^6$	$27 \times 10^5$	$18 \times 10^5$	$38 \times 10^6$
180	$12 \times 10^7$	$14 \times 10^7$	$14 \times 10^6$	$35 \times 10^6$	$33 \times 10^7$

Table V

Bactericidal activity of NBS against *Salmonella* Toucra O48

Time of incubation (min)	Serum concentration (%)				
	12.5	25	50	75	75 <sub>(NBS 56°C)</sub>
	CFU				
0	$52 \times 10^5$	$14 \times 10^5$	$16 \times 10^5$	$20 \times 10^5$	$20 \times 10^5$
60	$23 \times 10^5$	$84 \times 10^3$	$65 \times 10^3$	$39 \times 10^3$	$14 \times 10^6$
180	$23 \times 10^5$	$89 \times 10^3$	$60 \times 10^3$	$25 \times 10^3$	$18 \times 10^7$

Table VI

Bactericidal activity of NBS against *Citrobacter braakii* O37

Time of incubation (min)	Serum concentration (%)				
	12.5	25	50	75	75 <sub>(NBS 56°C)</sub>
	CFU				
0	$19 \times 10^5$	$18 \times 10^5$	$11 \times 10^5$	$12 \times 10^5$	$54 \times 10^5$
60	$90 \times 10^3$	$73 \times 10^3$	$67 \times 10^2$	$30 \times 10^2$	$21 \times 10^6$
180	$71 \times 10^3$	$18 \times 10^3$	$57 \times 10^2$	$29 \times 10^2$	$57 \times 10^6$

Table VII  
Bactericidal activity of NBS 50°C<sup>d</sup> and NBS MgEGTA<sup>e</sup>  
against *Escherichia coli* O56 after 0 min and 180 min  
of incubation

Time of incubation (min)	Serum concentration of NBS 50°C (%)			
	12.5	25	50	75
	CFU			
0	52 × 10 <sup>5</sup>	37 × 10 <sup>5</sup>	58 × 10 <sup>5</sup>	NT
180	16 × 10 <sup>6</sup>	67 × 10 <sup>4</sup>	45 × 10 <sup>1</sup>	NT
Time of incubation (min)	Serum concentration of NBS MgEGTA (%)			
	12.5	25	50	75
	CFU			
0	85 × 10 <sup>5</sup>	94 × 10 <sup>5</sup>	87 × 10 <sup>5</sup>	NT
180	56 × 10 <sup>5</sup>	39 × 10 <sup>5</sup>	82 × 10 <sup>4</sup>	NT

<sup>d</sup> NBS 50°C, serum with inhibited alternative pathway of complement activation (also relevant for tables VII–IX)

<sup>e</sup> NBS MgEGTA, serum with inhibited classical and lectin pathways of complement activation (relevant for Tables VII–IX)

Table VIII  
Bactericidal activity of NBS 50°C and NBS MgEGTA  
against *Salmonella* Toucra O48 after 0 min and 180 min  
of incubation

Time of incubation (min)	Serum concentration of NBS 50°C (%)			
	12.5	25	50	75
	CFU			
0	31 × 10 <sup>5</sup>	23 × 10 <sup>5</sup>	40 × 10 <sup>5</sup>	17 × 10 <sup>5</sup>
180	43 × 10 <sup>3</sup>	30 × 10 <sup>3</sup>	75 × 10 <sup>2</sup>	93 × 10 <sup>2</sup>
Time of incubation (min)	Serum concentration of NBS MgEGTA (%)			
	12.5	25	50	75
	CFU			
0	42 × 10 <sup>5</sup>	50 × 10 <sup>5</sup>	40 × 10 <sup>5</sup>	32 × 10 <sup>5</sup>
180	37 × 10 <sup>5</sup>	22 × 10 <sup>5</sup>	12 × 10 <sup>4</sup>	42 × 10 <sup>4</sup>

Table IX  
Bactericidal activity of NBS 50°C and NBS MgEGTA  
against *Citrobacter braakii* O37 after 0 min and 180 min  
of incubation

Time of incubation (min)	Serum concentration of NBS 50°C (%)			
	12.5	25	50	75
	CFU			
0	20 × 10 <sup>5</sup>	21 × 10 <sup>5</sup>	19 × 10 <sup>5</sup>	17 × 10 <sup>5</sup>
180	43 × 10 <sup>4</sup>	40 × 10 <sup>4</sup>	51 × 10 <sup>3</sup>	30 × 10 <sup>3</sup>
Time of incubation (min)	Serum concentration of NBS MgEGTA (%)			
	12.5	25	50	75
	CFU			
0	35 × 10 <sup>5</sup>	36 × 10 <sup>5</sup>	27 × 10 <sup>5</sup>	35 × 10 <sup>5</sup>
180	41 × 10 <sup>4</sup>	37 × 10 <sup>4</sup>	16 × 10 <sup>4</sup>	11 × 10 <sup>4</sup>

the classical and lectin pathways of complement activation were blocked (NBS MgEGTA). In this way the study of the bactericidal mechanisms of serum involved determination of the survival of bacteria in sera with certain bactericidal factors removed. In these experiments we used only *E. coli* O56, *S. Toucra* O48 and *C. braakii* O37 which were sensitive to the bactericidal action of complete NBS, because the strains resistant to complete NBS would also be resistant to the bactericidal action of modified serum (Tables VII–IX).

The obtained data indicate the same mechanisms of activation of complement. An important role for the classical and lectin pathways' mechanisms of complement activation was not observed. The dominant mechanism of activation of NBS was the independent activation of complement by the classical, lectin, and alternative pathways, in spite of the fact that all the tested strains have sialic acid in the O-specific antigen.

It was shown that the presence of sialic acid in LPS does not play a decisive role in the determination of bacterial resistance to the bactericidal activity of complement and that the presence of sialic acid in LPS is not sufficient to block of the amplification of the alternative pathway.

## Discussion

The differences between rough strains (R form) and smooth strains (S form) in their sensitivity to bactericidal action of serum have been demonstrated many times, including genetic confirmation of LPS O-specific chains participation in protection of the bacterial cell from the bactericidal action of complement (Delabac, 1968; Taylor, 1995). It has been shown (Doroszkiewicz *et al.*, 1994; Jankowski *et al.*, 1996; Mielnik *et al.*,

2001; Bugla *et al.*, 2004) that many smooth strains are sensitive to bactericidal action of complement. Our previous results also confirmed that the sensitivity of Gram-negative bacteria to normal cord serum (NCS) is variable (Mielnik *et al.*, 2001).

In the present experiments we used normal bovine serum (NBS). NCS and NBS presented different bactericidal activity. The bactericidal activity of NCS against some Gram-negative bacteria is less efficient than that of NBS. This effect is caused by a deficiency of complement components and a physiological deficiency of IgM antibodies in NCS (Jankowski, 1994; Cisowska and Jankowski, 2004).

*E. coli* O56 has a small number of repeating units in the O-chains of LPS (Gamian *et al.*, 1994) therefore these cells may be more sensitive to NBS than the S forms of *E. coli* O24, *E. coli* O104, *S. Toucra* O48 and *C. braakii* O37 (Gamian *et al.*, 1992; Gamian *et al.*, 1992a; Gamian *et al.*, 1994; Gamian *et al.*, 2000). *S. Toucra* O48 and *C. braakii* O37 (S form) were sensitive to the bactericidal action of NBS. The LPS of *S. Toucra* O48 and that of *C. braakii* O37 contain terminal non-reducing sialic acid (Neu5Ac), but the internal sialic acid in *S. Toucra* O48 LPS is 4-substituted, whereas that in *C. braakii* O37 is 7-substituted (Gamian and Kenne, 1993). In the tested strains of LPS endotoxins, except those of *E. coli* O104 the biological O-specific units are terminated at non-reducing end by sialic acid. In *E. coli* O104 antigen the biological O-specific unit has a terminal nonreducing galactose residue (Table I). Immunochemical analysis of the outer membrane showed that the differences in LPS structure could play an important role in determining the susceptibility of Gram-negative strains to the action of serum (Doroszkiwicz *et al.*, 1994; Doroszkiwicz, 1997). The phenomenon of serum resistance of bacteria has a multifactorial basis and the mechanism of bactericidal sensitivity and resistance to the bactericidal action of complement is not fully understood. In conclusion, sialic acid seems to be immunodominant in most of the studied antigens, but the presence of this molecule in LPS is not sufficient for bacterial resistance to bactericidal serum activity.

The *Neisseriae* strains can sialylate their lipooligosaccharide (LOS) and mimic sialylated lactoneo-glycosphingolipids, which may serve as a camouflage the bacterium to the host (Moran *et al.*, 1996). Serum-resistant strains of gonococci are known to be more sialylated (Rautemaa and Meri, 1999). Sialic acid, as a component of the cell of these bacteria, plays an essential role in protecting Gram-negative bacteria against the bactericidal activity of serum. Its protective effect is in the enhancement of the binding of factor H to the C3b component of the system which blocks the amplification loop, limiting the activation of the alternative pathway of complement activation. Factor H inhibits the alternative pathway's C3-convertase by dissociating Bb from the C3bBb complex and promotes the inactivation of C3b by factor I (Rautemaa and Meri, 1999). However, Neu5Ac, as a component of capsule K1 of *E. coli* does not interact directly with factor H and the mechanisms of alternative pathway blocking are not inhibited (Meri and Pangburn, 1990).

We determined the role of the particular mechanisms of complement activation in the process of killing Gram-negative bacilli with LPS containing sialic acid. The alternative complement pathway killed all the tested strains without the participation of antibodies. The independent activation of the classical, lectin, and alternative pathways in the serum was observed. This suggests that the tested strains do not have the ability to block the alternative pathway. Devine and Roberts (1994) showed that the possibility of blocking the alternative pathway is perhaps related to the amount of sialic acid on the cell surface. The exact role of sialic acid in LPS is not known. Microbial, immunological, structural and immunochemical studies on these LPS are necessary to understand the role of the sialic acid in interactions of prokaryotes cells with the cells of human and animal hosts.

**Acknowledgements.** The authors thank Prof. A. Gamian (Ludwik Hirsztfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland) for the *E. coli*, *Salmonella*, and *Citrobacter* strains from the Polish Collection of Microorganisms.

## Literature

- Bugla G., W. Doroszkiwicz, A. Gamian and A. Korzeniowska-Kowal. 2004. Bactericidal activity of normal human serum against Gram-negative bacilli with lipopolysaccharide-sialic acid (in Polish). *Med. Dośw. Microbiol.* **51**: 255–261.
- Cisowska A. and S. Jankowski. 2004. The sensitivity of *Escherichia coli* strains with K1 surface antigen and rods without this antigen to the bactericidal effect of serum. *Folia Microbiol.* **49**: 471–478.
- Delabac Y. 1968. The sensitivity of smooth and rough mutants of *Salmonella typhimurium* to bactericidal and bacteriolytic action of serum, lysozyme and phagocytosis. *Folia Microbiol.* **13**: 439–442.
- Devine D.A. and A.P. Roberts. 1994. K1, K5 and O-antigen *Escherichia coli* in relation to serum killing via the classical and alternative complement pathways. *J. Med. Microbiol.* **41**: 139–144.

- Doroszkiewicz W. 1997. Mechanism of antigenic variation in *Shigella flexnerii* bacilli. IV. Role of lipopolysaccharides and their components in the sensitivity of *Shigella flexnerii* 1b and its Lac<sup>+</sup> recombinant to killing action of serum. *Arch. Immunol. Ther. Exp.* **45**: 235–242.
- Doroszkiewicz W., R. Pokładek and T.M. Lachowicz. 1994. Mechanism of antigenic variation in *Shigella flexneri*. II. Sensitivity to complement as a selection factor for antigenic mutant 3b in 1b serotype. *Arch. Immunol. Ther. Exp.* **42**: 155–158.
- Edinger D., E. Bello and A. Mates. 1977. The heterocytotoxicity of human serum. I. Activation of the alternative complement pathway by heterologous target cells. *Cell Immunol.* **29**: 174–186.
- Egan W., T.-Y. Liu, D. Dorrow, J.S. Cohen, J.D. Robbins, E.C. Gotschlich and J.B. Robbins. 1977. Structural studies on the sialic acid polysaccharide antigen of *Escherichia coli* strain Bos-12. *Biochemistry* **16**: 3687–3692.
- Fine D.P., S.R. Marney, D.G. Colley, J.S. Sargent and R.M. Des Perez. 1972. C3 shunt activation in human serum chelated with EGTA. *J. Immunol.* **109**: 807–809.
- Gamian A. 1996. Studies on enterobacterial lipopolysaccharides containing sialic acid (in Polish). *Post. Microbiol.* **4**: 491–493.
- Gamian A., E. Romanowska, U. Dąbrowski and J. Dąbrowski. 1991. Structure of the O-specific sialic acid containing polysaccharide chain and its linkage to the core region in lipopolysaccharide from *Hafnia alvei* strain 2 elucidated by chemical methods gas-liquid chromatography/mass spectrometry and <sup>1</sup>H NMR spectroscopy. *Biochemistry* **30**: 5032–5038.
- Gamian A., E. Romanowska, J. Orlich and J. Defaye. 1992. The structure of sialic acid-containing O-specific polysaccharide and its linkage to the core region in lipopolysaccharide from *Escherichia coli* O104. *Carbohydr. Res.* **236**: 195–196.
- Gamian A., E. Romanowska, B. Szponar, U. Dąbrowski and J. Dąbrowski. 1992a. Structural and immunochemical studies of O-specific polysaccharides of *Salmonella* Toucra O48 and *Citrobacter freundii* O37. 2<sup>nd</sup> Conference International Endotoxin Society, Vienna, 1992. Abstr. 72.
- Gamian A., A. Romanowska and E. Romanowska. 1992b. Immunochemical studies on sialic acid-containing lipopolysaccharides from enterobacterial species. *FEMS Microbiol. Immunol.* **89**: 323–328.
- Gamian A. and L. Kenne. 1993. Analysis of 7-substituted sialic acid in some enterobacterial lipopolysaccharides. *J. Bacteriol.* **175**: 1508–1513.
- Gamian A., L. Kenne, M. Mieszkała, J. Urlich and J. Defaye. 1994. Structure of the *Escherichia coli* O24 and O56 O-specific sialic-acid-containing polysaccharides and linkage of these structures to the core region in lipopolysaccharides. *Eur. J. Biochem.* **225**: 1211–1212.
- Gamian A., T. Lipinski, A. Korzeniowska-Kowal and N. Ravenscroft. 2000. Structure of the sialic acid-containing O-specific polysaccharide from *Salmonella enterica* serovar Toucra O48 lipopolysaccharide. *Eur. J. Biochem.* **267**: 3160–3166.
- Jankowski S. 1994. The role of complement and antibodies in the impaired bactericidal activity of neonatal sera against Gram-negative bacteria. *Acta Microbiol. Pol.* **44**: 5–14.
- Jankowski S., S. Rowiński, A. Cisowska and A. Gamian. 1996. The sensitivity of *Hafnia alvei* strains to bactericidal effect of serum. *FEMS Immun. Med. Microb.* **13**: 59–64.
- Jann K. and B. Jann. 1977. Bacterial polysaccharides antigens. Surface carbohydrates of the prokaryotic cell. Ed: Sutherland I.W., Academic Press, London. pp. 247–297.
- Kędzierska B. 1978. N-acetylneuraminic acid: a constituent of the lipopolysaccharide of *Salmonella toucra*. *Eur. J. Biochem.* **91**: 545–552.
- Lachowicz M.T., W. Doroszkiewicz and J. Niedbach. 1999. Environment implication of lipopolysaccharide dependent normal serum sensitivity of *Shigella flexnerii* serotypes. *Nova Acta Leopoldina* **312**: 235–243.
- Marques M.B., D.L. Kasper, M.K. Pangburn and M.R. Wessels. 1992. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. *Infect. Immun.* **60**: 3986–3993.
- Matsushita M., Y. Mendo and T. Fujita. 1998. MASP-1 (MBL-associated serine protease 1). *Immunobiol.* **199**: 340–347.
- Meri S. and M.K. Pangburn. 1990. Discrimination between activators and nonactivators of the alternative pathway of complement regulation via a sialic acid/polyanion-binding site on factor H. *Proc. Natl. Acad. Sci. USA* **87**: 3982–3993.
- Mielnik G., A. Gamian and W. Doroszkiewicz. 2001. Bactericidal activity of normal cord serum (NCS) against Gram-negative rods with sialic acid-containing lipopolysaccharides (LPS). *FEMS Immunol. Med. Microbiol.* **31**: 169–173.
- Mokracka-Latajka G., S. Jankowski, K. Grzybek-Hryncewicz and B. Krzyżanowska. 1996. The mechanism of bactericidal action of normal human serum against *Salmonella* rods. *Acta Microbiol. Pol.* **45**: 169–180.
- Moran A.P., M.M. Prendergast and B.J. Appelmek. 1996. Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. *FEMS Med. Microbiol.* **16**: 105–115.
- Nastasi A., C. Mamma, M.R. Villafrate, M.F. Massenti, G. Scarlata and M. Diquatro. 1988. Multiple typing of strains of *Salmonella enterica* subsp. *bongori* ser. 48<sub>235</sub> isolated in southern Italy. *Ann. Inst. Pasteur Microbiol.* **139**: 605–612.
- Orskov I., F. Orskov, B. Jann and K. Jann. 1977. Serology, chemistry and genetics of O and K antigens of *Escherichia coli*. *Bacteriol. Rev.* **41**: 667–710.
- Ram S., F.G. Mackinnon, S. Gulati, D.P. McQuillen, U. Vogel, M. Frosch, C. Elkins, H.K. Guttormsen, L.M. Wetzter, M. Oppermann, M.K. Pangburn and P.A. Rice. 1999. The contrasting mechanisms of serum resistance of *Neisseria gonorrhoeae* and group B *Neisseria meningitidis*. *Molec. Immunol.* **36**: 915–928.
- Rautemaa R. and S. Meri. 1999. Complement-resistance mechanisms of bacteria. *Microb. Infect.* **1**: 785–794.
- Romanowska A., E. Katzenellenbogen, M. Kułakowska, A. Gamian, D. Witkowska, M. Kulczyk and E. Romanowska. 1988. *Hafnia alvei* lipopolysaccharides: isolation, sugar composition and SDS-PAGE analysis. *FEMS Microbiol. Immunol.* **47**: 151–156.
- Taylor P.W. 1995. Resistance of bacteria to complement. Virulence mechanism of bacterial pathogen. Roth, J.A., (Ed.) Am. Soc. Microbiol., Washington, D.C.
- Vimir E.R., K.A. Kalivoda, E.L. Deszo and S.M. Steenbergen. 2004. Diversity of microbial sialic acid metabolism. *Microbiol. Molec. Biol. Rev.* **68**: 132–153.